Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.

Cahn P, Pozniak AL, Mingrone H, Shuldyakov A, Brites C, Andrade-Villanueva JF, Richmond G, Buendia CB, Fourie J, Ramgopal M, Hagins D, Felizarta F, Madruga J, Reuter T, Newman T, Small CB, Lombaard J, Grinsztejn B, Dorey D, Underwood M, Griffith S, Min S; extended SAILING Study Team.

Lancet. 2013 Aug 24;382(9893):700-8. doi: 10.1016/S0140-6736(13)61221-0. Epub 2013 Jul 3. Erratum in: Lancet. 2014 Jan 4;383(9911):30.

PMID:
23830355
2.

[Scientific production in infectious diseases in Spain (1991-2001): position within the European Union].

Ramos-Rincón JM, Masiá Mdel M, Gutiérrez F.

Enferm Infecc Microbiol Clin. 2004 Jan;22(1):22-8. Spanish.

PMID:
14757004
3.

[Factors associated with resistance to human immunodeficiency virus protease inhibitors].

Moltó J, Gutiérrez F, Mora A, Masiá Mdel M, Escolano C, González E, Padilla S, Córdoba J, Hidalgo AM.

Med Clin (Barc). 2002 May 25;118(19):721-4. Spanish.

PMID:
12049703

Supplemental Content

Loading ...
Support Center